BRCA1 and ovarian cancer: The TOPACIO/KEYNOTE-162 Phase I/II study evaluated the combination of niraparib and pembrolizumab in patients with recurrent platinum-resistant ovarian cancer irrespective of BRCA1/2-mutation status [87].